Table 1.

Clinical characteristics of the cohort at initiation of POCY

CharacteristicWhiteBlackAsianHispanic
Male (n [%])20 (2)24 (1)11
Age (yr; median [range])33.0 (20.0 to 67.0)29.5 (20.0 to 49.0)32.022.0
Biopsy, WHO class (n [%])
    III5 (25.0)2 (8.3)
    IV10 (50.0)14 (58.0)11
    V3 (15.0)7 (29.0)
    unknown21
SCr (mg/dl; median [range])0.94 (0.60 to 4.40)1.18 (0.52 to 5.50)1.492.15
PC ratio3.60 (0.98 to 10.10)3.10 (0.74 to 16.50)6.302.50
C3 (mg/dl; median [range])71.0 (27.0 to 126.0)66.5 (5.0 to 208.0)58.068.0
C4 (mg/dl; median [range])9.5 (2.0 to 21.0)13.0 (5.0 to 55.0)a11.08.0
Initial dosage of CYC (mg/kg per d; median [range])1.3 (0.7 to 1.9)1.4 (0.5 to 1.7)1.21.5
Duration of CYC (mo; median [range])3.5 (1.0 to 8.0)4.0 (1.0 to 16.0)5.02.0
Total dosage of CYC (g; median [range])9.0 (3.0 to 22.0)10.5 (3.0 to 38.0)15.06.0
MMF after CYC (% of patients)71550100
AZA after CYC (% of patients)29451000
  • CYC, cyclophosphamide; SCr, serum creatinine; WHO, World Health Organization.

  • a P = 0.04 between black and white patients